Dear Sir, Please find the attachment. Regards, For MRC Agrotech Limited Compliance Officer/ Authorised Signatory

MRC Agrotech Ltd has filed its audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026 with BSE, with formal board approval scheduled for June 6, 2026. For the full year, revenue from operations surged to Rs 85.46 crore from Rs 32.45 crore a year ago (up roughly 163%), while profit after tax rose to Rs 1.17 crore from Rs 0.88 crore (up about 33%); Q4 revenue jumped to Rs 65.81 crore from Rs 21.05 crore. The auditor (Choudhary Choudhary & Co) issued an unmodified/unqualified opinion but flagged two emphasis-of-matter items: a Rs 16.85 crore share-swap acquisition making Marsapi Lifesciences a 100% subsidiary, and a Rs 7.30 crore loan assignment to Cicago Commodities. Key audit matters highlight heavy year-end revenue concentration (44.62% of taxable sales booked in March 2026), large trading volumes with two related counterparties (53% of purchases, 23% of sales), and GST classification gaps in GSTR-3B filings. Operating cash flow fell sharply to Rs 31.18 lakh from Rs 1.96 crore in FY25, pointing to working capital strain despite higher reported profits.